2024-514225-30-00已完成1 期
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra peptide in healthy volunteers
Universitaetsklinikum Heidelberg AöR1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2024年8月23日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 45
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Prof Dr med Antje Blank
Scientific
Universitaetsklinikum Heidelberg AöR
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOra-Peptide in healthy volunteersAcromegalyDRKS00032263niversität Heidelberg vertreten durch das Universitätsklinikum95
已完成
不适用
A phase 1 first-in-human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG232 in adult subjects with advanced solid tumors or multiple myelomasolide tumorentumor in the organsNL-OMON44939Amgen42
已完成
1 期
First-In-Human Pilot Study to Demonstrate the Safety and the Performance of the Cardiac Microcurrent Therapy System (CMIC System)I50.9Heart failure, unspecifiedDRKS00015708Berlin Heals GmbH10
已完成
1 期
A phase I clinical trial evaluating the safety of allogeneic Adipose Tissue-derived multilineage progenitor cells-transplantation therapy in severe familial hypercholesterolemia patientsSevere familial hypercholesterolemia (mainly homozygotes) undergoing LDL-apheresisJPRN-UMIN000020591Osaka University Graduate School of Medicine4
已完成
1 期
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Multiple MyelomaRelapsed or Refractory Acute Myeloid LeukemiaJPRN-jRCT2080224749Amgen K.K.175